Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate China Pharma Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding China Pharma Holdings, Inc.’s stock price such as:

• China Pharma Holdings, Inc.’s current stock price and volume
• Why China Pharma Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for CPHI from analysts
• CPHI’s stock price momentum as measured by its relative strength

About China Pharma Holdings, Inc. (CPHI)

Before we jump into China Pharma Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People’s Republic of China.

Want to learn more about China Pharma Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about China Pharma Holdings, Inc..

China Pharma Holdings, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 3:31 PM, CST, China Pharma Holdings, Inc.’s stock price was $1.125.

China Pharma Holdings, Inc. is down 13.46% from its previous closing price of $1.300.

During the last market session, China Pharma Holdings, Inc.’s stock traded between $1.080 and $1.280. Currently, there are approximately 25.60 million shares outstanding for China Pharma Holdings, Inc..

China Pharma Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

China Pharma Holdings, Inc. Stock Price History

China Pharma Holdings, Inc.’s (CPHI) price is currently up 70.43% so far this month.

During the month of July, China Pharma Holdings, Inc.’s stock price has reached a high of $19.190 and a low of $0.542.

Over the last year, China Pharma Holdings, Inc. has hit prices as high as $19.190 and as low as $0.382. Year to date, China Pharma Holdings, Inc.’s stock is down 7.02%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused China Pharma Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were analysts who downgraded China Pharma Holdings, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate China Pharma Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on China Pharma Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

China Pharma Holdings, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about China Pharma Holdings, Inc. (CPHI) by visiting AAII Stock Evaluator.

Relative Price Strength of China Pharma Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, China Pharma Holdings, Inc. has a weighted four-quarter relative price strength of 34.46%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how China Pharma Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

China Pharma Holdings, Inc. Stock Price: Bottom Line

As of July 31, 2026, China Pharma Holdings, Inc.’s stock price is $1.125, which is down 13.46% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like China Pharma Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.